Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 17;83(6):715–718. doi: 10.1054/bjoc.2000.1314

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine

M Nocera 1, E Baudin 1, G Pellegriti 1, A F Cailleux 1, C Mechelany-Corone 2, M Schlumberger 1; the Groupe d'Etude des Tumeurs a Calcitonine (GETC)1
PMCID: PMC2363532  PMID: 10952773

Abstract

Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations were observed. No unexpected toxicity occurred. © 2000 Cancer Research Campaign

Keywords: chemotherapy, medullary thyroid carcinoma

Full Text

The Full Text of this article is available as a PDF (46.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brierley J., Tsang R., Simpson W. J., Gospodarowicz M., Sutcliffe S., Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996 Aug;6(4):305–310. doi: 10.1089/thy.1996.6.305. [DOI] [PubMed] [Google Scholar]
  2. Chi D. D., Moley J. F. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin N Am. 1998 Oct;7(4):681–706. [PubMed] [Google Scholar]
  3. De Besi P., Busnardo B., Toso S., Girelli M. E., Nacamulli D., Simioni N., Casara D., Zorat P., Fiorentino M. V. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest. 1991 Jun;14(6):475–480. doi: 10.1007/BF03346846. [DOI] [PubMed] [Google Scholar]
  4. Di Bartolomeo M., Bajetta E., Bochicchio A. M., Carnaghi C., Somma L., Mazzaferro V., Visini M., Gebbia V., Tumolo S., Ballatore P. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol. 1995 Jan;6(1):77–79. doi: 10.1093/oxfordjournals.annonc.a059049. [DOI] [PubMed] [Google Scholar]
  5. Droz J. P., Schlumberger M., Rougier P., Ghosn M., Gardet P., Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990 Oct 31;76(5):480–483. doi: 10.1177/030089169007600513. [DOI] [PubMed] [Google Scholar]
  6. Fife K. M., Bower M., Harmer C. L. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol. 1996 Dec;22(6):588–591. doi: 10.1016/s0748-7983(96)92294-5. [DOI] [PubMed] [Google Scholar]
  7. Frame J., Kelsen D., Kemeny N., Cheng E., Niedzwiecki D., Heelan R., Lippermann R. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol. 1988 Aug;11(4):490–495. doi: 10.1097/00000421-198808000-00015. [DOI] [PubMed] [Google Scholar]
  8. Hoskin P. J., Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol. 1987 Nov;10(3):187–194. doi: 10.1016/s0167-8140(87)80004-x. [DOI] [PubMed] [Google Scholar]
  9. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  10. Moertel C. G., Johnson C. M., McKusick M. A., Martin J. K., Jr, Nagorney D. M., Kvols L. K., Rubin J., Kunselman S. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994 Feb 15;120(4):302–309. doi: 10.7326/0003-4819-120-4-199402150-00008. [DOI] [PubMed] [Google Scholar]
  11. Orlandi F., Caraci P., Berruti A., Puligheddu B., Pivano G., Dogliotti L., Angeli A. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol. 1994 Oct;5(8):763–765. doi: 10.1093/oxfordjournals.annonc.a058984. [DOI] [PubMed] [Google Scholar]
  12. Petursson S. R. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer. 1988 Nov 1;62(9):1899–1903. doi: 10.1002/1097-0142(19881101)62:9<1899::aid-cncr2820620905>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  13. Saad M. F., Ordonez N. G., Rashid R. K., Guido J. J., Hill C. S., Jr, Hickey R. C., Samaan N. A. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984 Nov;63(6):319–342. [PubMed] [Google Scholar]
  14. Schlumberger M., Abdelmoumene N., Delisle M. J., Couette J. E. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 1995 Feb;71(2):363–365. doi: 10.1038/bjc.1995.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shimaoka K., Schoenfeld D. A., DeWys W. D., Creech R. H., DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985 Nov 1;56(9):2155–2160. doi: 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  16. Tubiana M., Haddad E., Schlumberger M., Hill C., Rougier P., Sarrazin D. External radiotherapy in thyroid cancers. Cancer. 1985 May 1;55(9 Suppl):2062–2071. doi: 10.1002/1097-0142(19850501)55:9+<2062::aid-cncr2820551406>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  17. Williams S. D., Birch R., Einhorn L. H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986 Mar;70(3):405–407. [PubMed] [Google Scholar]
  18. Wu L. T., Averbuch S. D., Ball D. W., de Bustros A., Baylin S. B., McGuire W. P., 3rd Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer. 1994 Jan 15;73(2):432–436. doi: 10.1002/1097-0142(19940115)73:2<432::aid-cncr2820730231>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  19. Yang K. P., Liang Y. F., Samaan N. A. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res. 1991 May-Jun;11(3):1065–1068. [PubMed] [Google Scholar]
  20. van Heerden J. A., Grant C. S., Gharib H., Hay I. D., Ilstrup D. M. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990 Oct;212(4):395–401. doi: 10.1097/00000658-199010000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES